Biocon Limited Announces 48th AGM on Aug 6, 2026, Releases Integrated Annual Report FY26
Biocon Limited will hold its 48th AGM on August 6, 2026. The company released its Integrated Annual Report for FY26, showing total income of ₹172,695 million and EBITDA of ₹37,978 million. A final dividend of ₹0.50 per share was announced. The report details progress in biosimilars, generics, and CRDMO businesses, alongside sustainability efforts.
The announcement concerns the Annual General Meeting and the release of the annual report, which are important for shareholders and investors to understand the company's performance and future direction. The detailed financial and operational information presented in the annual report has a medium impact.
The announcement is a routine corporate communication regarding the AGM and the release of the annual report. It contains factual information about past performance and future meetings without significant positive or negative implications.
Biocon Limited has announced its 48th Annual General Meeting (AGM) will be held on Thursday, August 06, 2026, at 3:30 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM), in compliance with relevant regulations. The company has also released its Integrated Annual Report for the Financial Year 2025-26, which includes the Business Responsibility and Sustainability Report (BRSR), GRI, and ESG Data Book as supplements. Both the AGM notice and the Integrated Annual Report are available on Biocon's website. The report details the company's performance across its Biosimilars, Generics, CRDMO, and Novel Biologics segments, highlighting financial and non-financial achievements, sustainability initiatives, and strategic priorities. Key financial highlights for FY26 include total income of ₹172,695 million (USD 1.96 billion), growing 14%, and EBITDA of ₹37,978 million (USD 430 million), growing 25% with an EBITDA margin of 22%. The company also announced a final dividend of ₹0.50 per share. The report emphasizes Biocon's commitment to making healthcare more accessible and affordable, with over 23 million patients benefiting from its generics and biosimilars in FY26. The integration of Biocon Biologics into Biocon Limited is highlighted as a significant structural move to create a unified global biopharmaceutical enterprise. Shreehas Tambe has been welcomed as the new Chief Executive Officer and Managing Director.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.